Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant plasmid hepatocyte growth factor injection for severe lower limb ischemic rest pain
CTR20181274Phase 3Completed
- Sponsor
- Institute of Radiation Medicine, Academy of Military Medical Sciences
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of olamepermin alfa in arteriosclerosis obliterans, sponsored by Institute of Radiation Medicine, Academy of Military Medical Sciences. Started Aug 2018; status: completed.
02
Drugs
olamepermin alfa
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20181274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181274.